<DOC>
	<DOCNO>NCT00655161</DOCNO>
	<brief_summary>This consolidation therapy trial evaluate GI-4000 subject NSCLC treat curative intent disease free first post-treatment restaging assessment .</brief_summary>
	<brief_title>A Pilot Phase 2 Trial Immunogenicity , Safety GI-4000 ; Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein , Consolidation Therapy Following Curative Treatment Stage I-III Non-Small Cell Lung Cancer ( NSCLC ) With Tumor Sequence Confirmation K-ras Mutation</brief_title>
	<detailed_description>NSCLC deadly form human cancer , kill approximately 150,000 people year United States . The best treatment NSCLC surgical resection . For patient inoperable unresectable NSCLC chemotherapy radiation use first line therapy . This consolidation therapy trial evaluate GI-4000 subject NSCLC treat curative intent disease free first post-treatment restaging assessment . These subject must also ras mutation .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Pathologically proven stage IIII NSCLC Confirmed product relate ras mutation ECOG performance status less equal 2 great equal 18 year age History previous cancer History splenectomy History Crohns disease ulcerative colitis History major organ transplantation Concurrent chronic steroid therapy History allergy yeast Presence unstable poorly control medical condition Pregnant nursing mother Positive skin test yeast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Cancer Immunotherapy</keyword>
</DOC>